Skip to main content

Table 3 Multivariable analysis for PFS adjusted by treatment and metastatic volume

From: The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study

 

HR

95 % CI for HR

p-value

Mets Volume (High vs. Low)

2.66

(1.34, 5.27)

0.005

Treatment (ADT + Chemo vs. ADT)

1.09

(0.65, 1.84)

0.75

 Insulin (ln)a (<2.1 vs. ≥2.1)

2.55

(1.24, 5.23)

0.011

 HGF (ln)a (>8.9 vs. ≤8.9)

2.00

(1.08, 3.70)

0.027

 OPN (ln)a (>11.9 vs. ≤11.9)

1.67

(0.84, 3.33)

0.147

C-peptide (ln) (Unit = 1000)

0.97

(0.86, 1.10)

0.622

  1. OPN osteopontin, HGF hepatocyte growth factor
  2. aCut points were determined by CART analysis
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us